FDA needs more info on Dynavax's hepatitis B vaccine
This article was originally published in Scrip
Executive Summary
The FDAhas asked Dynavax for additional data before the company can resume clinical development of its investigational hepatitis B vaccine Heplisav in the US, the company said.